BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study
Phase 2
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Nifedipine (Adalat CR, BAYA1040) 40mg ODDrug: Nifedipine (Adalat CR, BAYA1040) 40mg BIDDrug: Nifedipine (Adalat CR, BAYA1040) 80mg OD
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2015-06-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 35
- Registration Number
- NCT00768560
Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)
Phase 3
Completed
- Conditions
- Infection, Intra-abdominal
- Interventions
- Drug: Ceftriaxone + MetronidazoleDrug: Avelox (Moxifloxacin, BAY12-8039)
- First Posted Date
- 2008-10-08
- Last Posted Date
- 2014-12-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 364
- Registration Number
- NCT00769171
Long-term Treatment on BAY77-1931 (Lanthanum Carbonate) to Measure Lanthanum Concentrations in Bone
Phase 2
Completed
- Conditions
- HyperphosphatemiaDialysis
- Interventions
- Drug: Lanthanum Carbonate (BAY77-1931)
- First Posted Date
- 2008-10-07
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT00767637
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
Phase 3
Completed
- Conditions
- Gastric AcidHuman Experimentation
- Interventions
- Drug: Omeprazole/sodium bicarbonateDrug: omeprazole magnesium (20 mg equivalent)
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2015-03-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 60
- Registration Number
- NCT00765206
Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.
Phase 4
Completed
- Conditions
- Neoplastic CNS Lesions
- Interventions
- Drug: Gadovist® (Gadobutrol, BAY86-4875)Drug: Dotarem
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2014-12-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 166
- Registration Number
- NCT00764387
Health Economic Evaluation of Primovist-enhanced Liver MRI
Phase 4
Completed
- Conditions
- Colorectal NeoplasmsNeoplasm Metastasis
- Interventions
- Procedure: Extracellular contrast media (ECCM) MRIProcedure: Primovist MRIProcedure: Contrast-enhanced CT
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 360
- Registration Number
- NCT00764621
Effects of SH T00658ID on Libido
Phase 3
Completed
- Conditions
- LibidoContraception
- Interventions
- Drug: MicrogynonDrug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)Drug: Placebo
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 217
- Registration Number
- NCT00764881
- Locations
- 🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇹Clin Pharm International GmbH Studienzentrum Wien, Wien, Austria
🇦🇺Sydney Centre for Reproductive Health Reseach, Ashfield, New South Wales, Australia
Pilot Study of Safety and Efficacy of Spheramine
Phase 2
Terminated
- Conditions
- Parkinson''s Disease
- Interventions
- Biological: Spheramine (BAY86-5280)
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6
- Registration Number
- NCT00761436
BAY 0 9867 Cipro Pediatric Use Study (QUIP)
Phase 3
Completed
- Conditions
- Infectious Diseases
- Interventions
- Drug: Non-quinolone antibioticDrug: Ciprofloxacin
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1029
- Registration Number
- NCT00761462
Pharmacodynamic Characterization of Dienogest
Phase 1
Completed
- Conditions
- Pharmacodynamics
- Interventions
- Drug: Dienogest (81150231)Drug: Dienogest (SH T00660A)Drug: Dienogest (81150037)Drug: Dienogest (81150746)
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT00754871
© Copyright 2025. All Rights Reserved by MedPath